Silexion Therapeutics Corp, a Cayman Islands-based company, announced on May 22, 2025, that it received a delisting notice from the Nasdaq Listing Qualifications Department. The notice pertains to the company's failure to comply with Nasdaq Listing Rules 5450(b)(2)$(A)$ and 5450(b)(2)$(C)$, which require maintaining a minimum Market Value of Listed Securities of $50 million and a Market Value of Publicly Held Shares of $15 million. Despite a 180-day compliance period ending May 19, 2025, Silexion was unable to rectify these deficiencies. The company plans to appeal the decision before the Nasdaq Hearings Panel by May 29, 2025. If the appeal is unsuccessful, trading of its shares and warrants will be suspended on June 2, 2025, and a Form 25-NSE will be filed with the SEC to remove its securities from Nasdaq listing. Additionally, Silexion intends to apply for a transfer to the Nasdaq Capital Market, contingent upon meeting the required Equity Standard.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。